Landmark Bio and Mass General Brigham partner to accelerate translational CGT therapies
Charlie Blackie-Kelly | October 30, 2025 | News story | Research and Development | Landmark Bio, Mass General Brigham, cell and gene therapies, partnership
Landmark Bio and Mass General Brigham in the US have entered a new strategic collaboration designed to accelerate the development of early-stage cell and gene therapies (CGTs) and shorten the time it takes for innovative treatments to reach patients.
“This collaboration underscores our shared mission to bring breakthrough therapies to patients faster,” said Ran Zheng, chief executive officer of Landmark Bio. “Working with the exceptional teams at the Mass General Brigham Gene and Cell Therapy Institute (GCTI), we are excited to provide the infrastructure and expertise that can help translate cutting-edge science into real-world impact.”
Under the agreement, Landmark Bio – a drug development and end-to-end solutions provider for pharmaceutical and biotechnology companies – will provide development and manufacturing support for translational CGT programmes across the Mass General Brigham network, in collaboration with the GCTI.
According to both partners, the framework will streamline the path from discovery to clinic by integrating research, development and manufacturing capabilities. This approach aims to remove common barriers in translational science and enable faster progression of investigational therapies through to clinical evaluation and potential scale-up.
“The GCTI exists to help realise the promise of cell and gene therapies developed by investigators across Mass General Brigham,” said Roger J Hajjar, head of the GCTI at Mass General Brigham. “This collaboration with Landmark Bio reflects our commitment to translational science and working together with collaborators to move transformative therapies forward.”
Related Content
Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis
Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a …
PM Society and CIM launch new leadership programme for pharma marketers
The Pharmaceutical Marketing (PM) Society has partnered with the Chartered Institute of Marketing (CIM) to …
Chiesi partners with Key2Brain to develop therapies for rare neurodegenerative diseases
Italian biopharma, Chiesi Group, and Key2Brain, a Swedish biotech, have agreed to advance the development …
